about
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapyPharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects.Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes.Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulationEffect of renal function on the bioavailability of ciprofloxacinSteady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients.Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysisRelationships between renal function and disposition of oral ciprofloxacinSteady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa.Pharmacokinetics of quinolones: newer aspects.Interethnic differences in pharmacokinetics of antibacterials.Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones.Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones.Electrospun polyvinyl alcohol-polyvinyl pyrrolidone nanofibrous membranes for interactive wound dressing application.Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding.Effect of dose size on bioavailability of ciprofloxacin.Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.Transport of gemifloxacin, a 4th generation quinolone antibiotic, in the Caco-2 and engineered MDCKII cells, and potential involvement of efflux transporters in the intestinal absorption of the drug.Antimicrobial drugs encapsulated in fibrin nanoparticles for treating microbial infested wounds.Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis.Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats.Carbamoyl translocations by an anionic ortho-fries and cumulenolate alpha-acylation pathway: regioselective synthesis of polysubstituted chromone 3- and 8-carboxamides.A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin.Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats.A Review on Triple Antibiotic Paste as a Suitable Material Used in Regenerative Endodontics.
P2860
Q33740530-D45EA222-AB54-4B16-BF38-95CC185741FDQ34454737-287618A3-3796-40F1-B3F5-3E4DDB994821Q35114003-70E846B0-C6AE-42CD-8C82-CB18032A4A98Q35121273-6E2235D9-C0B9-411C-924B-4E2BD7B1CD0FQ35210471-6498A108-7214-47C8-A41A-103D8F63E820Q35258939-604A7EBF-EF9C-4D90-9579-E652C3314ECEQ35359695-49116EAA-AA64-486F-84B9-7462A92CFE5DQ35543479-43C52060-A3F9-4CB5-B2C3-08E813EA72EDQ35564482-28666845-7BD6-4F67-9B26-70BD2B420C36Q36757441-CD404243-0F22-436A-A1F9-E026FE26753DQ37222580-A4A8399B-2F3D-4968-BEB1-005000652559Q38266806-A2DB1AA8-E8D0-4B2A-A675-BF57F2A4BA14Q38271416-28B2EB0D-ECC6-45F5-BAE9-FFB34AD2F506Q38427273-77BD617B-16C5-4B0B-9CDE-48CB4ADA077AQ38819194-BDB04152-3D55-4D61-85F4-6BF20BF0A0DDQ39214819-84634246-CCBE-46C5-B8F6-475988824EF3Q39833111-6D72E166-D35F-45A9-B9C7-115CDA779E32Q40283886-FD1EB175-D6C2-4104-9175-42D327882582Q41071899-F17BD21C-F047-4C91-AEAB-A555C1FB35C5Q42513426-2F596957-0768-4125-A76A-D06BB63BBAC0Q43893250-B93FF928-0A4E-499F-9D0A-2F3593F39495Q44023516-CB433129-7E90-4830-AE92-BF2775434828Q44930646-DD3C18D0-AA68-4972-9F4F-0B8D4F09094CQ46760288-29C3E34B-1F21-4359-A858-5EE27279A580Q52081442-126F89A9-BF30-4CB2-8D42-B681CF5ABB44Q54449662-14B61355-CD26-43AA-A54A-28278CD62D51Q54996288-AF7C6514-B650-49CF-833C-D37048F99BC6
P2860
description
1986 nî lūn-bûn
@nan
1986 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Absolute oral bioavailability of ciprofloxacin
@ast
Absolute oral bioavailability of ciprofloxacin
@en
Absolute oral bioavailability of ciprofloxacin
@nl
type
label
Absolute oral bioavailability of ciprofloxacin
@ast
Absolute oral bioavailability of ciprofloxacin
@en
Absolute oral bioavailability of ciprofloxacin
@nl
prefLabel
Absolute oral bioavailability of ciprofloxacin
@ast
Absolute oral bioavailability of ciprofloxacin
@en
Absolute oral bioavailability of ciprofloxacin
@nl
P2093
P2860
P356
P1476
Absolute oral bioavailability of ciprofloxacin
@en
P2093
G L Drusano
H C Standiford
J Caldwell
K Plaisance
P2860
P356
10.1128/AAC.30.3.444
P407
P577
1986-09-01T00:00:00Z